Quantification of pinosylvin in rat plasma by liquid chromatography-tandem mass spectrometry: application to a pre-clinical pharmacokinetic study.
Pinosylvin (trans-3,5-dihydroxystilbene), a naturally occurring analogue of resveratrol (trans-3,5,4'-trihydoxystilbene), exhibited various beneficial pharmacological activities in pre-clinical studies. To further probe its potential medicinal application, a sensitive liquid chromatography-tandem mass spectrometry method (LC-MS/MS) was developed and validated for the quantification of pinosylvin in rat plasma. A simple protein precipitation procedure was used for plasma cleanup before analysis by LC-MS/MS with electrospray ionisation and multiple reaction monitoring in its negative ion mode. This LC-MS/MS method demonstrated good selectivity, accuracy (intra- and inter-day analytical recovery within 100±7.7%), precision (intra- and inter-day coefficient of variation<12.0%) and sensitivity (lower limit of detection=1.0ng/mL), with excellent linearity (R(2)>0.99) over the range of 1-1000ng/mL. The pharmacokinetic profiles of pinosylvin were subsequently assessed in Sprague-Dawley rats. Following intravenous administration (5 or 10mg/kg), plasma levels of pinosylvin declined rapidly with a short half-life (t1/2<10min). Upon oral administration at 15mg/kg, pinosylvin could not be quantified in plasma (<1ng/mL) while dose-escalation to 50mg/kg led to a low and erratic plasma exposure with very poor estimated oral bioavailability (F<1%). The short half-life and limited systemic exposure of pinosylvin prompt caution in its therapeutic application and it warrants exploration in developing pinosylvin pro-drug.